257 related articles for article (PubMed ID: 27448155)
1. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus.
Kurt A; Andican G; Siva ZO; Andican A; Burcak G
J Physiol Biochem; 2016 Dec; 72(4):679-687. PubMed ID: 27448155
[TBL] [Abstract][Full Text] [Related]
2. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-α levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial.
Houjeghani S; Kheirouri S; Faraji E; Jafarabadi MA
Nutr Res; 2018 Jan; 49():96-106. PubMed ID: 29420997
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Taurine Supplementation on Metabolic Profiles, Pentosidine, Soluble Receptor of Advanced Glycation End Products and Methylglyoxal in Adults With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
Esmaeili F; Maleki V; Kheirouri S; Alizadeh M
Can J Diabetes; 2021 Feb; 45(1):39-46. PubMed ID: 32861603
[TBL] [Abstract][Full Text] [Related]
4. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
[TBL] [Abstract][Full Text] [Related]
5. Pentosidine and N-carboxymethyl-lysine: biomarkers for type 2 diabetic retinopathy.
Ghanem AA; Elewa A; Arafa LF
Eur J Ophthalmol; 2011; 21(1):48-54. PubMed ID: 20544678
[TBL] [Abstract][Full Text] [Related]
6. Pentosidine plasma levels and relation with metabolic control in diabetic patients.
Lapolla A; Reitano R; Baccarin L; Sartore G; Plebani M; Fedele D
Horm Metab Res; 2005 Apr; 37(4):252-6. PubMed ID: 15952087
[TBL] [Abstract][Full Text] [Related]
7. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
[TBL] [Abstract][Full Text] [Related]
8. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Yubero-Serrano EM; Woodward M; Poretsky L; Vlassara H; Striker GE;
Clin J Am Soc Nephrol; 2015 May; 10(5):759-66. PubMed ID: 25710801
[TBL] [Abstract][Full Text] [Related]
9. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes.
Hirata K; Kubo K
Endocr J; 2004 Dec; 51(6):537-44. PubMed ID: 15644571
[TBL] [Abstract][Full Text] [Related]
10. Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
O'Grady KL; Khosla S; Farr JN; Bondar OP; Atkinson EJ; Achenbach SJ; Eckhardt BA; Thicke BS; Tweed AJ; Volkman TL; Drake MT; Hines JM; Singh RJ
J Appl Lab Med; 2020 May; 5(3):558-568. PubMed ID: 32445362
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
12. Impaired osteogenic differentiation and enhanced cellular receptor of advanced glycation end products sensitivity in patients with type 2 diabetes.
Phimphilai M; Pothacharoen P; Kongtawelert P; Chattipakorn N
J Bone Miner Metab; 2017 Nov; 35(6):631-641. PubMed ID: 27873077
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy.
Ng ZX; Chua KH; Iqbal T; Kuppusamy UR
Int J Mol Sci; 2013 Apr; 14(4):7480-91. PubMed ID: 23552832
[TBL] [Abstract][Full Text] [Related]
14. Prebiotic supplementation modulates advanced glycation end-products (AGEs), soluble receptor for AGEs (sRAGE), and cardiometabolic risk factors through improving metabolic endotoxemia: a randomized-controlled clinical trial.
Farhangi MA; Dehghan P; Namazi N
Eur J Nutr; 2020 Oct; 59(7):3009-3021. PubMed ID: 31728681
[TBL] [Abstract][Full Text] [Related]
15. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
[TBL] [Abstract][Full Text] [Related]
16. AGE-RAGE Interaction Does Not Explain the Clinical Improvements after Therapeutic Fasting in Osteoarthritis.
Drinda S; Franke S; Schmidt S; Stoy K; Lehmann T; Wolf G; Neumann T
Complement Med Res; 2018; 25(3):167-172. PubMed ID: 29433120
[TBL] [Abstract][Full Text] [Related]
17. Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE).
Nowak A; Przywara-Chowaniec B; Damasiewicz-Bodzek A; Blachut D; Nowalany-Kozielska E; Tyrpień-Golder K
Cells; 2021 Dec; 10(12):. PubMed ID: 34944030
[TBL] [Abstract][Full Text] [Related]
18. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.
Barzilay JI; Jablonski KA; Fonseca V; Shoelson SE; Goldfine AB; Strauch C; Monnier VM;
Diabetes Care; 2014 Apr; 37(4):1083-91. PubMed ID: 24255104
[TBL] [Abstract][Full Text] [Related]
19. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
Kanazawa I; Yamamoto M; Yamaguchi T; Sugimoto T
Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):362-5. PubMed ID: 21472665
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
